ATE376001T1 - Kondensiertes protein, das sowohl thrombolytisch als auch gerinnungshemmend wirkt, und dessen verwendung - Google Patents

Kondensiertes protein, das sowohl thrombolytisch als auch gerinnungshemmend wirkt, und dessen verwendung

Info

Publication number
ATE376001T1
ATE376001T1 AT03793572T AT03793572T ATE376001T1 AT E376001 T1 ATE376001 T1 AT E376001T1 AT 03793572 T AT03793572 T AT 03793572T AT 03793572 T AT03793572 T AT 03793572T AT E376001 T1 ATE376001 T1 AT E376001T1
Authority
AT
Austria
Prior art keywords
protein
thrombolytic
anticolotting
actions
linker peptide
Prior art date
Application number
AT03793572T
Other languages
English (en)
Inventor
Bingxing Shi
Zuze Wu
Aiping Yu
Chunna Dong
Original Assignee
Inst Radiation Med Amms Pla
Beijing Lu Yin Li Hua Pharmace
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Radiation Med Amms Pla, Beijing Lu Yin Li Hua Pharmace filed Critical Inst Radiation Med Amms Pla
Application granted granted Critical
Publication of ATE376001T1 publication Critical patent/ATE376001T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03793572T 2002-09-03 2003-09-03 Kondensiertes protein, das sowohl thrombolytisch als auch gerinnungshemmend wirkt, und dessen verwendung ATE376001T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA021290865A CN1480466A (zh) 2002-09-03 2002-09-03 一类溶栓抗凝双功能融合蛋白及应用

Publications (1)

Publication Number Publication Date
ATE376001T1 true ATE376001T1 (de) 2007-11-15

Family

ID=31954566

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03793572T ATE376001T1 (de) 2002-09-03 2003-09-03 Kondensiertes protein, das sowohl thrombolytisch als auch gerinnungshemmend wirkt, und dessen verwendung

Country Status (8)

Country Link
US (1) US8212003B2 (de)
EP (1) EP1541589B1 (de)
JP (2) JP2006516113A (de)
CN (2) CN1480466A (de)
AT (1) ATE376001T1 (de)
AU (1) AU2003261606A1 (de)
DE (1) DE60316967T2 (de)
WO (1) WO2004022598A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102443065A (zh) * 2005-06-01 2012-05-09 中国人民解放军军事医学科学院放射与辐射医学研究所 特异性抗凝血物质的制备及其应用
CN1896108B (zh) * 2005-06-01 2012-01-04 中国人民解放军军事医学科学院放射与辐射医学研究所 特异性抗凝血物质的制备及其应用
EP1816201A1 (de) * 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
WO2007132481A2 (en) * 2006-05-12 2007-11-22 Bharat Biotech International Limited Novel thrombolytic molecules and a process therefor
US8101379B2 (en) 2006-12-15 2012-01-24 Institute of Radiation Medicine Academy of Military Medical Science Preparation of low bleeding anticoagulant fusion protein and its use
CN100519585C (zh) * 2007-02-06 2009-07-29 中国人民解放军军事医学科学院基础医学研究所 P11与sak的融合蛋白及其制备方法和用途
DK2109457T3 (en) * 2007-02-12 2016-04-11 Csl Behring Gmbh THERAPEUTIC USE OF KAZAL TYPE SERINE PROTEASE INHIBITORS
KR102069498B1 (ko) * 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
DE102009010611A1 (de) * 2009-02-25 2010-08-26 Siemens Aktiengesellschaft Vorrichtung und Verfahren zur Steuerung einer mit mehreren Brennern ausgestatteten Turbine für flüssige oder gasförmige Brennstoffe
AU2011287360A1 (en) * 2010-08-05 2013-02-21 Council Of Scientific & Industrial Research Protein fusion constructs possessing thrombolytic and anticoagulant properties
CN102180973B (zh) * 2011-03-18 2012-08-29 重庆大学 靶向多功能防栓融合蛋白及其制备方法和应用
MX2015002985A (es) * 2012-09-07 2015-06-22 Sanofi Sa Proteinas de fusion para el tratamiento de un sindrome metabolico.
CN106366200B (zh) * 2015-07-23 2020-04-10 武汉光谷人福生物医药有限公司 制备重组葡激酶-水蛭素融合蛋白的方法
JP7028904B2 (ja) * 2019-03-21 2022-03-02 アカデミア シニカ 合成ペプチド、それを備える薬学的組成物及び血栓塞栓症関連疾患の治療におけるその使用
CN113150168B (zh) * 2021-01-29 2022-11-11 武汉真福医药股份有限公司 一种qk纤溶酶基因-水蛭素融合蛋白的制备方法及应用
KR102789819B1 (ko) * 2021-10-21 2025-03-31 중앙대학교 산학협력단 트롬빈 검출용 신규한 펩타이드 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
US5759542A (en) * 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US6015787A (en) * 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
US6423680B1 (en) * 1998-10-30 2002-07-23 Hsc Research And Development Limited Partnership Inhibitor of platelet activating factor
CN1188522C (zh) * 2001-07-20 2005-02-09 健力福生化技术（上海）有限公司 一种血栓靶向性溶栓蛋白表达质粒及其构建
CN1181099C (zh) * 2002-07-23 2004-12-22 中国人民解放军第二军医大学 兼抗凝溶栓双重功能的血栓靶向融合蛋白mA5UKB

Also Published As

Publication number Publication date
AU2003261606A1 (en) 2004-03-29
EP1541589A1 (de) 2005-06-15
EP1541589B1 (de) 2007-10-17
CN1678636A (zh) 2005-10-05
DE60316967D1 (de) 2007-11-29
CN1480466A (zh) 2004-03-10
DE60316967T2 (de) 2008-05-08
JP2006516113A (ja) 2006-06-22
JP2010184930A (ja) 2010-08-26
CN1301268C (zh) 2007-02-21
US8212003B2 (en) 2012-07-03
WO2004022598A1 (fr) 2004-03-18
US20060127389A1 (en) 2006-06-15
EP1541589A4 (de) 2005-11-16

Similar Documents

Publication Publication Date Title
DE60316967D1 (de) Kondensiertes protein, das sowohl thrombolytisch als auch gerinnungshemmend wirkt, und dessen verwendung
EP1624891A4 (de) Gerinnungsfaktor-fc chimere proteine zur behandlung von hämophilie
DE602004011770D1 (de) Fusionsproteine
DE502004012225D1 (de) Generierung künstlicher bindungsproteine auf der grundlage von ubiquitin-proteinen
NO20053872L (no) Fusjonskonstruksjoner og anvendelse av disse for fremstilling av antistoffer med okt FC-reseptorbindingsaffinitet og effektorfunksjon.
ATE342359T1 (de) Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
DE10075010I1 (de) Fusionsproteine mit immunglobulinanteilen ihre Herstellung und Verwendung
MY154826A (en) Fusion protein capable of binding vegf
Tsuda et al. Synthesis of cysteine-rich peptides by native chemical ligation without use of exogenous thiols
EP1688488A4 (de) Biospezifischer antikörper als ersatz für funktionelle proteine
ATE513043T1 (de) Gegen denaturierungsmittel stabile und/oder proteaseresistente, chaperonähnliche oligomere proteine, diese kodierende polynukleotide sowie ihre verwendungen
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
JPH0689014B2 (ja) トロンビン結合性物質およびその製法
ATE306498T1 (de) Von zellen präsentierte peptide
EP1574518A3 (de) VEGF-artiges Protein aus Schlangengift mit spezifischer Bindungsaktivität an VEGF-Rezeptor Typ 2 und dessen Verwendung
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
GB2451044A (en) Novel thrombolytic molecules and a process therefor
DE69634994D1 (de) Bindegewebe-wachstumsfaktor 3.
RU2008108806A (ru) Набор лиофилизированного тромбина и лиофилизированного фибриногена, используемый для приготовления фибриновой мембраны, и его применение
CN1286262A (zh) 人胎盘抗凝蛋白介导的新型抗凝蛋白
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
Fischer et al. Purification of recombinant human coagulation factors II and IX and protein S expressed in recombinant Vaccinia virus-infected Vero cells
ATE290549T1 (de) Ing2, ein mit iaps assoziiertes zellzyklusprotein,sowie zusammensetzungen, verfahren und verwendungen
Zhong Role of the first epidermal growth factor-like domain in factor IX function.
RU2003121258A (ru) Способ получения полигалактуроназного ферментного препарата

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties